JW SHINYAK CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,823 KRW | +0.05% |
|
+2.47% | -26.49% |
| Sales 2022 | 103B 74.05M 6.18B | Sales 2023 | 104B 75.15M 6.27B | Capitalization | 126B 90.66M 7.57B |
|---|---|---|---|---|---|
| Net income 2022 | 1.4B 1.01M 84.25M | Net income 2023 | -37.36B -26.93M -2.25B | EV / Sales 2022 | 1.81 x |
| Net Debt 2022 | 10.61B 7.65M 639M | Net Debt 2023 | 9.04B 6.52M 544M | EV / Sales 2023 | 1.29 x |
| P/E ratio 2022 |
127
x | P/E ratio 2023 |
-3.36
x | Employees | 231 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.05% | ||
| 1 week | +2.47% | ||
| Current month | -9.08% | ||
| 1 month | -9.08% | ||
| 3 months | -14.81% | ||
| 6 months | -18.20% | ||
| Current year | -26.49% |
1 week
1 777.00
1 842.00
1 month
1 705.002 060.00
Current year
1 705.002 500.00
1 year
1 705.003 166.67
3 years
1 705.005 668.93
5 years
1 705.006 252.54
10 years
1 705.0012 463.94
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Ho Baek
CEO | Chief Executive Officer | 63 | 16/17/16 |
Pil-Kyu Kim
IND | Independent Dir/Board Member | 65 | 08/21/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Ho Baek
CEO | Chief Executive Officer | 63 | 16/17/16 |
Pil-Kyu Kim
IND | Independent Dir/Board Member | 65 | 08/21/08 |
Myung-Chul Lee
BRD | Director/Board Member | 75 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 1,823 | +0.05% | 50,495 |
| 29/24/29 | 1,822 | +1.28% | 47,803 |
| 26/24/26 | 1,799 | +1.01% | 23,790 |
| 25/24/25 | 1,781 | -1.49% | 77,613 |
| 24/24/24 | 1,808 | +1.12% | 69,957 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
JW SHINYAK CORPORATION is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Companyâs main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.49% | 66.77M | |
| +3.37% | 69.25B | |
| +13.27% | 9B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +21.69% | 2.45B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B |
- Stock Market
- Equities
- A067290 Stock
